Form D · Biotechnology
Nuago Therapeutics, Inc.
Chicago, IL · CIK 0001950101
Offering snapshot reported Nov 8, 2022 · SEC filing
- Reported sold
- $150K Offering amount: $3.6M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 25, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 8, 2022 | Initial | $150,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-464163
Source: Form D, filed Nov 8, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dr. Andrea E. Murmann | Director, Executive |
| Dr. Marcus E. Peter | Director |
| Dr. Robert Schickel | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
875 North Michigan Avenue Suite 3100
Chicago, IL, 60611
Chicago, IL, 60611